Sep 29, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Sep 29, 2025 • Benzinga
SOMEWHAT-BULLISH
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Sep 12, 2025 • Motley Fool
NEUTRAL
This Under-the-Radar Healthcare Stock Could Soar in 2026
We should know a lot more by year-end.
Aug 29, 2025 • Benzinga
SOMEWHAT-BULLISH
Steven Cohen's Biotech Bets Are Getting Bolder - And Smaller - Invivyd ( NASDAQ:IVVD )
Steven Cohen bought $17.2 million of Invivyd on Tuesday. Point72 liftedDesign stake by 62.8% on Wednesday. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day Steven Cohen isn't afraid of volatility - and his latest moves show he's diving headfirst into small-cap biotech.
Aug 24, 2025 • CNBC
NEUTRAL
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Aug 19, 2025 • Benzinga
NEUTRAL
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →